Drug intelligence / Profile preview

bupivacaine + nalbuphine

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intrathecal

Overview

A combination of bupivacaine, a local anesthetic, and nalbuphine, a synthetic opioid agonist-antagonist. When administered intrathecally (into the spinal canal), this combination provides enhanced and prolonged analgesia for various surgical procedures. Bupivacaine works by blocking sodium channels to inhibit nerve conduction, while nalbuphine binds to kappa opioid receptors in the spinal cord to produce analgesia with antagonist effects at mu opioid receptors. This combination offers extended duration of sensory blockade and postoperative pain relief with fewer side effects compared to other opioid adjuvants.

Other names: Nalbuphine-Bupivacaine combination

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on bupivacaine + nalbuphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + nalbuphine.

Explore the full profile